Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about GlycoMimetics, Inc.
GlycoMimetics, Inc. News
Jul 25, 2024 - businesswire.com
GlycoMimetics Announces Strategic Review and Corporate Restructuring Plan
Jun 4, 2024 - businesswire.com
GlycoMimetics Announces Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
May 29, 2024 - businesswire.com
GlycoMimetics to Host Key Opinion Leader Event to Review Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) on June 4, 2024
May 9, 2024 - seekingalpha.com
GlycoMimetics, Inc. (GLYC) Corporate Update Call Transcript
GlycoMimetics, Inc. Quantitative Score
About GlycoMimetics, Inc.
GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as in phase 3 trial to treat relapsed/refractory AML. In addition, the company is developing GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of cancers that affect the bone and bone marrow, including solid tumors. It also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and galectin-3 antagonists, a carbohydrate-binding protein. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.
GlycoMimetics, Inc. Earnings & Revenue
GlycoMimetics, Inc. Financials
Table Compare
Compare GLYC metrics with: | |||
|---|---|---|---|
Earnings & Growth | GLYC | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | GLYC | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | GLYC | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | GLYC | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
GlycoMimetics, Inc. Income
GlycoMimetics, Inc. Balance Sheet
GlycoMimetics, Inc. Cash Flow
GlycoMimetics, Inc. Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Strong Buy |
| Return on Equity | Strong Sell |
| Return on Assets | Strong Sell |
| Debt/Equity Ratio | Neutral |
| Price/Earnings Ratio | Strong Sell |
| Price/Book Ratio | Neutral |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
GlycoMimetics, Inc. Valuation
Project future cash flows and get the intrinsic value per share.
Historical Market Cap
Shares Outstanding
GlycoMimetics, Inc. Executives
| Name | Role |
|---|---|
| Mr. Harout Semerjian | Chief Executive Officer, President & Director |
| Mr. Brian M. Hahn | Senior Vice President & Chief Financial Officer |
| Dr. Edwin Rock M.D., Ph.D. | Senior Vice President & Chief Medical Officer |
| Ms. Rachel K. King | Co-Founder & Director |
| Mr. Shantha Tyavanagimatt Ph.D. | Senior Vice President of Technical Operations |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Mr. Harout Semerjian | Chief Executive Officer, President & Director | Male | 1970 | 1.13M |
| Mr. Brian M. Hahn | Senior Vice President & Chief Financial Officer | Male | 1974 | 822.12K |
| Dr. Edwin Rock M.D., Ph.D. | Senior Vice President & Chief Medical Officer | 1961 | 677.4K | |
| Ms. Rachel K. King | Co-Founder & Director | Female | 1959 | 40K |
| Mr. Shantha Tyavanagimatt Ph.D. | Senior Vice President of Technical Operations | Male | -- |
GlycoMimetics, Inc. Insider Trades
| Date | 7 Aug |
| Name | Invus Public Equities, L.P. |
| Role | 10 percent owner |
| Transaction | Disposed |
| Type | S-Sale |
| Shares | 61488 |
| Date | 8 Aug |
| Name | Invus Public Equities, L.P. |
| Role | 10 percent owner |
| Transaction | Disposed |
| Type | S-Sale |
| Shares | 260873 |
| Date | 5 Aug |
| Name | Invus Public Equities, L.P. |
| Role | 10 percent owner |
| Transaction | Disposed |
| Type | S-Sale |
| Shares | 164523 |
| Date | 6 Aug |
| Name | Invus Public Equities, L.P. |
| Role | 10 percent owner |
| Transaction | Disposed |
| Type | S-Sale |
| Shares | 55732 |
| Date | 1 Aug |
| Name | Invus Public Equities, L.P. |
| Role | 10 percent owner |
| Transaction | Disposed |
| Type | S-Sale |
| Shares | 63564 |
| Date | Name | Role | Transaction | Type | Shares |
|---|---|---|---|---|---|
| 7 Aug | Invus Public Equities, L.P. | 10 percent owner | Disposed | S-Sale | 61488 |
| 8 Aug | Invus Public Equities, L.P. | 10 percent owner | Disposed | S-Sale | 260873 |
| 5 Aug | Invus Public Equities, L.P. | 10 percent owner | Disposed | S-Sale | 164523 |
| 6 Aug | Invus Public Equities, L.P. | 10 percent owner | Disposed | S-Sale | 55732 |
| 1 Aug | Invus Public Equities, L.P. | 10 percent owner | Disposed | S-Sale | 63564 |